[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Collagen Solutions Plc LSE:COS London Ordinary Share GB00B94T6Y14 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 6.625 6.25 7.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 4.0 -3.7 -0.8 - 30

Collagen Solutions Share Discussion Threads

Showing 576 to 599 of 850 messages
Chat Pages: 34  33  32  31  30  29  28  27  26  25  24  23  Older
DateSubjectAuthorDiscuss
06/12/2017
08:50
Continues to disappoint/ only people getting fat on this crock of sh#t are the execs
interstellar
05/12/2017
16:25
Management expects to increase sales by 5 times when 2021 comes around and today result didn’t help their cause. The fall in revenue came from lower sales in North America and Asia. The first six-month saw losses grew to £1.38m, the expectation of a higher revenue didn’t materialise. Crucially, they have enough financing in place with Cash and cash equivalent at £6.74m. But, the company didn’t allude to net funds dropping from £7.07m to £3.8m in six months. Mostly due to increases in debt. Collagen paid deferred consideration of £1m to NZ based Southern Lights Biomaterials (an acquisition made in 2014) by drawing down a £1m bond with an interest rate of 10%. Bad news and lack of confidences from lenders. To understand 7 things Collagen Solutions, click http://bit.ly/2jgYt9o
walbrock82
22/11/2017
11:46
I'm not sure if the medics have much faith in some of the concepts. f
fillipe
27/10/2017
08:10
fillipe - Agreed - Interesting and needed product - provided if performs as promised but going nowhere fast - Marked down 1st thing and what appear to be significant sells coming through -
pugugly
26/10/2017
18:16
Hi Pug, you're welcome. I'm not in here, but keep a watch. I had COS early 2016 for a small gain, but then lost out later that year on a re-buy. It's their forever losing the precious £££; which I couldn't take, even for a pharma it gets tiring. There's great talking the talk there, but it must be wearing a bit thin, although the words of future success seem to slip along with ease. I'll keep watching for now as I think you are correct about future falls .....some of the past subscribers must be well cheesed off. Dec 5 for the int's seems light years away. gl and all best, g
fillipe
26/10/2017
17:02
fillipe: Thansk for heads up Could be further falls tomorrow then.
pugugly
26/10/2017
17:01
Disappointing sales. Heard this excuse about delays in customer's projects before and quite unacceptable after the first such occurence. Budget should reflect these probabilities/ possibilities since they seem to be a recurring theme. Need more irons in the fire to compensate. Getting mighty fed up waiting for this lot to perform
interstellar
26/10/2017
16:26
Downgraded to Sell sign raised by Hot Stock Rockets, today. f
fillipe
26/10/2017
16:19
Looking very soggy Sales volume building towards close - Not a GSK but share price action similar !!
pugugly
28/9/2017
14:34
Investor presentation by Collagen Solutions CEO Jamal Rushdy at the Hardman & Co’s Investors Forum 20th September 2017. Http://www.piworld.co.uk/2017/09/27/collagen-solutions-cos-hardman-cos-investor-forum-presentation-september-2017/ Collagen Solutions develops, manufactures and supplies medical grade collagen biomaterials for use in research, medical devices, and regenerative medicine. Introduction – 00:20 Regenerative medicine – 00:44 What Collagen Solutions do: 2:17 How will Collagen Solutions Grow? – 4:12 About collagen and tissue biomaterials – 7:00 Growing the core biomaterials business – 8:32 The competition – 12:00 Collagen Solution’s USP – 13:05 Proprietary products pipeline – 15:04 Financial Highlights – 18:36 Growth & investor proposition – 19:00 Q&A Knee surgery recovery – 19:45 The regulatory process – 20:28 Demand & supply of collagen – 21:41 Why bovine tissue? & immune reaction? – 22:50
tomps2
25/9/2017
09:52
Thanks tim. CE mark nailed on. Timescale after operation study and stats no one in the world can match. Very happy to watch this one build... whilst being invested, I bought a portion slightly higher like others, but I've also averaged down considerably. DYOR
jacobjohn7
22/9/2017
01:23
Collagen Solutions were at the Hardman Conference last night, Jamal had a 20 min slot followed by Q&As, he talked about this extended trial and was emphasising its importance, a couple of the Q&As at the end were on the extended study too. It was recorded on video, so it should be available on the Hardman web site shortly, there is also a new Hardman research report updated to reflect recent progress on their web site too http://www.hardmanandco.com/docs/default-source/company-docs/collagen-solutions-plc-documents/21.09.17-engineering-towards-ce-mark.pdf
timbo003
21/9/2017
18:32
Glad you said that inter I feel exactly the same. I bought at 7p but my waiting has turned me into a skeleton.
1toad
21/9/2017
08:30
I admire such consistent and patient enthusiasm. I am 60% down on my investment and i'm getting a bit tired of these jam tomorrow announcements and still the share price goes nowhere.
interstellar
21/9/2017
08:08
Positive announcement again this morning. If they can get CE mark, that's a large market for them to aim at.
18bt
30/8/2017
20:36
anyone get any titbits from agm?
jacobjohn7
23/8/2017
14:08
Any thoughts on timings etc for the CE mark etc? They could be waiting to make an impact at the AGM?
jacobjohn7
28/7/2017
09:17
you mean figures wise dan? When the inhouse products get approval and release we will move.
jacobjohn7
26/7/2017
21:15
Link to Hardman report (dated July 25th 2017) referred to above: http://www.hardmanandco.com/docs/default-source/company-docs/collagen-solutions-plc-documents/cos---2017-results---25-july-2017.pdf
timbo003
26/7/2017
11:16
The report from Hardman was slightly less positive than their previous report of 2 months earlier
danieldruff2
25/7/2017
11:44
Read the report, and all seems well, obviously there are several intangibles at this stage, that if all come to fruition, could make this a very big company!
jacobjohn7
25/7/2017
11:42
Collagen Solutions PLC Director/PDMR Shareholding 25/07/2017 11:36am UK Regulatory (RNS & others) Collagen Sol (LSE:COS) Intraday Stock Chart Today : Tuesday 25 July 2017 Click Here for more Collagen Sol Charts. TIDMCOS RNS Number : 0283M Collagen Solutions PLC 25 July 2017 This announcement contains inside information Collagen Solutions Plc (the "Company") Director/PDMR Dealing Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it was notified today that David Evans, Chairman of the Company, has purchased 900,000 ordinary shares in the Company ("Ordinary Shares") at 5.1 pence per Ordinary Share. Following the transaction, David Evans' total beneficial holding in the Company has increased to 39,394,554 Ordinary Shares representing 12.15 per cent. of the issued ordinary share capital of the Company. Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
jacobjohn7
12/7/2017
08:00
New Interview (and article) on Proactiveinvestor: http://www.proactiveinvestors.co.uk/companies/stocktube/7771/collagen-solutions-jamal-rushdie-hails-significant-growth-in-asia-pacific-europe-7771.html http://www.proactiveinvestors.co.uk/companies/news/180711/collagen-solutions-moves-up-the-medtech-value-chain-180711.html
timbo003
07/7/2017
12:53
Jamal Rushdy, CEO of Collagen Solutions said: "We are excited to begin the clinical assessment of long-term scaffold performance in patients who received the ChondroMimetic® implant. To our knowledge, ChondroMimetic® will be the only known, 'unpartnered' product with such long-term clinical evidence, significantly differentiating it from competing therapies. This extension study represents a critical step forward in our ChondroMimetic® development programme, which has the potential to address 450,000 annual cartilage procedures and provide access to a US $500M-$1B market opportunity via a novel, proprietary technology." There looks to be a very big market in the america alone.
slartybartfaster
Chat Pages: 34  33  32  31  30  29  28  27  26  25  24  23  Older
ADVFN Advertorial
Your Recent History
LSE
COS
Collagen S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211019 00:16:40